687 - Invasive fusariosis in the era of mold active azoles and molecular targeted chemotherapy: Increasing incidence and lack of improved outcomes

Rapid Fire Presenter(s)

• 

  Takahiro Matsuo, MD

  Clinical Fellow
  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States

  Disclosure: Disclosure(s): No financial relationships to disclose

Co-Author(s)

• 

  Sebastian Wurster, MD, MSc.

  Assistant Professor
  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• YJ

  Ying Jiang, MS

  Research Statistical Analyst
  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• KS

  Koji Sasaki, MD, PhD

  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• JT

  Jeffrey J. Tarrand, MD

  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• RL

  Russell E. Lewis, PharmD

  University of Bologna
  Bologna, Emilia-Romagna, Italy

  Disclosure: Disclosure(s): Air: Advisor/Consultant (); Cidara: Advisor/Consultant (); F2G: Advisor/Consultant (); Gilead: Advisor/Consultant (); Merck & Co, Inc: Grant/Research Support (); Synexis: Advisor/Consultant ()
• 

  Dimitrios P. Kontoyiannis, MD

  Professor, Infectious Diseases
  The University of Texas MD Anderson Cancer Center
  Houston, TX, United States

  Disclosure: Disclosure(s): No financial relationships to disclose